Determination of camostat and its metabolites in human plasma - Preservation of samples and quantification by a validated UHPLC-MS/MS method

被引:2
|
作者
Sorensen, Lambert K. [1 ]
Hasselstrom, Jorgen B. [1 ]
Gunst, Jesper D. [2 ]
Sogaard, Ole S. [2 ]
Kjolby, Mads [3 ,4 ,5 ]
机构
[1] Aarhus Univ, Dept Forens Med, Sect Forens Chem, Aarhus, Denmark
[2] Aarhus Univ Hosp, Dept Infect Dis, Aarhus, Denmark
[3] Aarhus Univ Hosp, Dept Clin Pharmacol, Aarhus, Denmark
[4] Aarhus Univ, DANDRITE, Dept Biomed, Aarhus, Denmark
[5] Aarhus Univ Hosp, Steno Diabet Ctr Aarhus, Aarhus, Denmark
关键词
Camostat; FOY-305; GBPA; FOY-251; GBA; COVID-19; Esterase inhibitors; LC-MS/MS; PROTEASE INHIBITOR; BILIARY-EXCRETION; RAT; TMPRSS2;
D O I
10.1016/j.clinbiochem.2021.07.007
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Objectives: Camostat mesilate is a drug that is being repurposed for new applications such as that against COVID-19 and prostate cancer. This induces a need for the development of an analytical method for the quantification of camostat and its metabolites in plasma samples. Camostat is, however, very unstable in whole blood and plasma due to its two ester bonds. The molecule is readily hydrolysed by esterases to 4-(4-guanidinobenzoyloxy)phenylacetic acid (GBPA) and further to 4-guanidinobenzoic acid (GBA). For reliable quantification of camostat, a technique is required that can instantly inhibit esterases when blood samples are collected. Design and methods: An ultra-high-performance liquid chromatography-tandem mass spectrometry method (UHPLC-ESI-MS/MS) using stable isotopically labelled analogues as internal standards was developed and validated. Different esterase inhibitors were tested for their ability to stop the hydrolysis of camostat ester bonds. Results: Both diisopropylfluorophosphate (DFP) and paraoxon were discovered as efficient inhibitors of camostat metabolism at 10 mM concentrations. No significant changes in camostat and GBPA concentrations were observed in fluoride-citrate-DFP/paraoxon-preserved plasma after 24 h of storage at room temperature or 4 months of storage at-20 degrees C and-80 degrees C. The lower limits of quantification were 0.1 ng/mL for camostat and GBPA and 0.2 ng/mL for GBA. The mean true extraction recoveries were greater than 90%. The relative intralaboratory reproducibility standard deviations were at a maximum of 8% at concentrations of 1-800 ng/mL. The trueness expressed as the relative bias of the test results was within +/- 3% at concentrations of 1-800 ng/mL. Conclusions: A methodology was developed that preserves camostat and GBPA in plasma samples and provides accurate and sensitive quantification of camostat, GBPA and GBA by UHPLC-MS/MS.
引用
收藏
页码:56 / 62
页数:7
相关论文
共 50 条
  • [1] A validated UHPLC-MS/MS method for rapid determination of senicapoc in plasma samples
    Sorensen, Lambert K.
    Petersen, Asbjorn
    Granfeldt, Asger
    Simonsen, Ulf
    Hasselstrom, Jorgen B.
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2021, 197
  • [2] Determination of imidacloprid in beehive samples by UHPLC-MS/MS
    Michlig, Melina P.
    Merke, Julieta
    Pacini, Adriana C.
    Orellano, Emanuel M.
    Beldomenico, Horacio R.
    Repetti, Maria R.
    MICROCHEMICAL JOURNAL, 2018, 143 : 72 - 81
  • [3] Quantification of soy isoflavones and their conjugative metabolites in plasma and urine: an automated and validated UHPLC-MS/MS method for use in large-scale studies
    Soukup, Sebastian T.
    Al-Maharik, Nawaf
    Botting, Nigel
    Kulling, Sabine E.
    ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2014, 406 (24) : 6007 - 6020
  • [4] Detection of banned nitrofuran metabolites in animal plasma samples using UHPLC-MS/MS
    Radovnikovic, Anita
    Moloney, Mary
    Byrne, Paddy
    Danaher, Martin
    JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2011, 879 (02): : 159 - 166
  • [5] Development of a UHPLC-MS/MS Method for the Determination of Moxidectin in Rat Plasma and Its Application in Pharmacokinetics
    Zhang, Hongjuan
    Yang, Zhen
    Hao, Baocheng
    Wu, Di
    Shao, Dan
    Liu, Yu
    Pu, Wanxia
    Yi, Shouli
    Shang, Ruofeng
    Wang, Shengyi
    MOLECULES, 2024, 29 (20):
  • [6] Development of a UHPLC-MS/MS method for the quantification of ilaprazole enantiomers in rat plasma and its pharmacokinetic application
    Ou, Fengting
    Zhou, Ying
    Lei, Jinxiu
    Zeng, Su
    Wu, Fuhai
    Zhang, Ning
    Yu, Lushan
    JOURNAL OF PHARMACEUTICAL ANALYSIS, 2020, 10 (06) : 617 - 623
  • [7] Validated UHPLC-MS/MS assay for quantitative determination of etoposide, gemcitabine, vinorelbine and their metabolites in patients with lung cancer
    Gong, Xiaobin
    Yang, Le
    Zhang, Feng
    Liang, Youtian
    Gao, Shouhong
    Liu, Ke
    Chen, Wansheng
    BIOMEDICAL CHROMATOGRAPHY, 2017, 31 (11)
  • [8] Validated LC-MS/MS Method for Simultaneous Determination of Aripiprazole and its Three Metabolites in Human Plasma
    Suzuki, Yusuke
    Naito, Takafumi
    Kawakami, Junichi
    CHROMATOGRAPHIA, 2017, 80 (12) : 1805 - 1812
  • [9] UHPLC-MS/MS-based method for quantification of verinurad in rat plasma and its application in a bioavailability study
    Guo, Ziyu
    Yuan, Wenjing
    Zhu, Xinru
    Jiang, Zhenzhou
    Zhang, Zunjian
    Huang, Xin
    BIOMEDICAL CHROMATOGRAPHY, 2022, 36 (11)
  • [10] Development and validation of a sensitive and rapid UHPLC-MS/MS method for the simultaneous quantification of the common active and inactive metabolites of vicagrel and clopidogrel in human plasma
    Liu, Cai
    Lu, Youming
    Sun, Hongbin
    Yang, Jin
    Liu, Yongqiang
    Lai, Xiaojuan
    Gong, Yanchun
    Liu, Xuefang
    Li, Yongguo
    Zhang, Yifan
    Chen, Xiaoyan
    Zhong, Dafang
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2018, 149 : 394 - 402